Table 3.
Binding Profiles of mAbs to Recombinant Subdomains of HER2-ECD by ELISA
mAbs | DI | DI+DII | DII | DIII | DIII+DIV | DIV | HER2-ECD |
---|---|---|---|---|---|---|---|
1F2 | ++ | ++ | - | - | - | - | ++ |
1T0 | - | ++ | - | - | - | - | ++ |
2A8 | - | - | - | - | ++ | - | ++ |
2A9 | ++ | ++ | - | - | - | - | ++ |
1H6 | ++ | ++ | - | - | - | - | ++ |
1H9 | - | - | - | - | ++ | ++ | ++ |
1B5 | - | - | - | - | ++ | - | ++ |
4C7 | - | - | - | + | ++ | - | ++ |
Pertuzumab | - | - | - | - | - | - | ++ |
Trastuzumab | - | - | - | - | ++ | - | ++ |
Anti-HER2 polyclonal Ab | ++ | ++ | - | + | ++ | ++ | ++ |
Anti –His Ab | + | ++ | ++ | + | ++ | ++ | ++ |
Trastuzumab, Pertuzumab and anti-HER2 polyclonal antibodies are used as positive controls. Full HER2-ECD is also employed as positive control in the coating layer. Anti-His mAb was used to verify the coated recombinant proteins. The results represent OD values of <0.2 (-), 1.0-2.0 (+) and >2.0 (++)